CRISPR THERAPEUTICS AG
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|
| Revenue | $3.1M | $41.0M | $5.2M | $247.0K | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Gross Margin | — | — | — | — | — |
| Operating Expenses | |||||
| Research & Development | $113.8M | $69.8M | $42.2M | $12.6M | $1.5M |
| SG&A Expense | $48.3M | $35.8M | $31.1M | $13.4M | $5.1M |
| Operating Income | $-158.9M | $-64.6M | $-68.1M | $-25.7M | $-6.6M |
| Operating Margin | -5,087.8% | -157.7% | -1,319.3% | -10,416.6% | — |
| Interest Expense | — | — | — | — | — |
| Pretax Income | $-164.4M | $-66.6M | $-22.7M | $-25.8M | $-6.9M |
| Income Tax Expense | $553.0K | $1.7M | $484.0K | $7.0K | $-63.0K |
| Net Income | $-165.0M | $-68.4M | $-23.2M | $-25.5M | $-7.0M |
| Net Margin | -5,281.1% | -166.7% | -448.8% | -10,325.1% | — |
| EPS (Basic) | $-3.44 | $-1.71 | $-1.89 | $-5.06 | $1.97 |
| EPS (Diluted) | $-3.44 | $-1.71 | $-1.89 | $-5.06 | $1.97 |
| Shares Outstanding (Basic) | 48.0M | 40.1M | 39.7M | 5.5M | — |
| Shares Outstanding (Diluted) | 48.0M | 40.1M | 39.7M | 5.5M | — |
| Dividends Per Share | — | — | — | — | — |